236 related articles for article (PubMed ID: 33902424)
21. Breast cancer immunotherapy: Current and novel approaches.
Barzaman K; Moradi-Kalbolandi S; Hosseinzadeh A; Kazemi MH; Khorramdelazad H; Safari E; Farahmand L
Int Immunopharmacol; 2021 Sep; 98():107886. PubMed ID: 34153663
[TBL] [Abstract][Full Text] [Related]
22. New Immunotherapy Strategies in Breast Cancer.
Yu LY; Tang J; Zhang CM; Zeng WJ; Yan H; Li MP; Chen XP
Int J Environ Res Public Health; 2017 Jan; 14(1):. PubMed ID: 28085094
[TBL] [Abstract][Full Text] [Related]
23. Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y; Zhu X; Tang C; Guan X; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
[TBL] [Abstract][Full Text] [Related]
24. Pharmacotherapeutic options for patients with refractory breast cancer.
Fedele P; Ciccarese M; Surico G; Cinieri S
Expert Opin Pharmacother; 2019 May; 20(7):851-861. PubMed ID: 30730767
[TBL] [Abstract][Full Text] [Related]
25. Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.
Gingras I; Azim HA; Ignatiadis M; Sotiriou C
Clin Adv Hematol Oncol; 2015 Jun; 13(6):372-82. PubMed ID: 26352893
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer vaccination: Latest advances with an analytical focus on clinical trials.
Vajari MK; Sanaei MJ; Salari S; Rezvani A; Ravari MS; Bashash D
Int Immunopharmacol; 2023 Oct; 123():110696. PubMed ID: 37494841
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab in the Treatment of Breast Cancer.
Maximiano S; Magalhães P; Guerreiro MP; Morgado M
BioDrugs; 2016 Apr; 30(2):75-86. PubMed ID: 26892619
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy as a partner for HER2-directed therapies.
Clifton GT; Peoples AGE
Expert Rev Anticancer Ther; 2021 Jul; 21(7):739-746. PubMed ID: 33666116
[No Abstract] [Full Text] [Related]
29. Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence.
Abbaspour M; Akbari V
Expert Rev Vaccines; 2022 Mar; 21(3):337-353. PubMed ID: 34932427
[TBL] [Abstract][Full Text] [Related]
30. Emerging immunotherapeutic strategies for the treatment of breast cancer.
Huppert LA; Mariotti V; Chien AJ; Soliman HH
Breast Cancer Res Treat; 2022 Jan; 191(2):243-255. PubMed ID: 34716870
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
32. Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.
Xu J; Bao H; Wu X; Wang X; Shao YW; Sun T
Oncol Lett; 2019 Jul; 18(1):449-455. PubMed ID: 31289516
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
34. Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer.
Sun X; Liu K; Lu S; He W; Du Z
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358874
[TBL] [Abstract][Full Text] [Related]
35. [Adjuvant treatment of operable breast cancer].
Khosravi Shahi P; Izarzugaza Perón Y; Encinas García S; Díaz Muñoz de la Espada VM; Pérez Manga G
An Med Interna; 2008 Jan; 25(1):36-40. PubMed ID: 18377195
[TBL] [Abstract][Full Text] [Related]
36. "Triple positive" breast cancer - a novel category?
Iancu G; Vasile D; Iancu RC; DaviŢoiu DV
Rom J Morphol Embryol; 2017; 58(1):21-26. PubMed ID: 28523293
[TBL] [Abstract][Full Text] [Related]
37. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
38. Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer.
Pack CD; Bommireddy R; Munoz LE; Patel JM; Bozeman EN; Dey P; Radhakrishnan V; Vartabedian VF; Venkat K; Ramachandiran S; Reddy SJC; Selvaraj P
Hum Vaccin Immunother; 2020 Dec; 16(12):3184-3193. PubMed ID: 32530786
[TBL] [Abstract][Full Text] [Related]
39. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Martin M; López-Tarruella S
Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
[TBL] [Abstract][Full Text] [Related]
40. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
André F; Neven P; Marinsek N; Zhang J; Baladi JF; Degun R; Benelli G; Saletan S; Jerusalem G
Curr Med Res Opin; 2014 Jun; 30(6):1007-16. PubMed ID: 24490834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
